Tirzepatide (10mg)
Tirzepatide is a 39-amino acid dual incretin receptor agonist that activates both the GLP-1 and GIP receptors. This 10 mg vial reduces the number of vials needed at higher maintenance doses. A half-life of ~5 days allows for convenient weekly subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Tirzepatide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Tirzepatide is a novel dual agonist that simultaneously activates the GLP-1 and GIP receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The ~5-day half-life allows for convenient weekly administration.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual titration every 4 weeks).
- Storage: Lyophilized: freezer at −20 °C; after reconstitution, refrigerator at 2–8 °C; use within 28 days.
Typical / Gradual Approach (2 mL = 5.0 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 50 Units (0.50 mL) |
| Weeks 5–8 | 5 mg | 100 Units (1.00 mL) |
| Weeks 9–12 | 7.5 mg | 2 × 75 Units (0.75 mL) |
| Weeks 13–16 | 10 mg | 2 × 100 Units (1.00 mL) |
| Weeks 17+ | 15 mg | 3 × 100 Units (1.00 mL) |
Studies report administration once weekly subcutaneously on the same day each week. For doses >1.0 mL, split into two injections at different sites. Increase dose every 4 weeks.
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water with a sterile syringe.
- Slowly inject down the side of the vial; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Mark reconstitution date and refrigerate at 2–8 °C, protected from light.
- Use within 28 days of reconstitution.
Protocol Overview
- Objective: Support for glycemic control, weight management, and metabolic health via dual incretin receptor activation.
- Schedule: Weekly subcutaneous injection on the same day for 12–16+ weeks.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Dosing Protocol
- Initiation: 2.5 mg once weekly for 4 weeks.
- Escalation: Increase by 2.5 mg every 4 weeks if tolerated.
- Maintenance: 5–15 mg weekly based on response.
- Frequency: Once weekly (subcutaneously), same day.
- Break between cycles: After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide has a half-life of ~5 days—sufficient clearance time is required before a new cycle.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide has a half-life of ~5 days—sufficient clearance time is required before a new cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; do not freeze the reconstituted solution.
- Shelf life: Use within 28 days after reconstitution.
- Allow vials to reach room temperature before opening.
Important Notes
- For doses >1.0 mL, split into multiple injections at different sites.
- GI side effects (nausea, diarrhea) are minimized with gradual titration.
Potential Benefits & Side Effects
Potential Benefits:
- Glycemic control: Significant reductions in HbA1c.
- Weight reduction: Up to ~11 kg more than GLP-1 mono-agonists.
- Cardiovascular markers: Improvements in lipid profiles and blood pressure.
- Larger vial: Fewer vials at higher maintenance doses.
Potential Side Effects:
- Gastrointestinal: Nausea, diarrhea, vomiting, constipation—usually mild and dose-dependent.
- Injection site reactions: Occasional mild redness.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
Same warning as GLP-1 RAs. C-cell tumors in rodents. Contraindicated in MTC/MEN 2.
📄 FDA Boxed Warning — Mounjaro® LabelAcute pancreatitis
Risk of acute pancreatitis. Reported in post-marketing surveillance.
📄 FDA Label — Mounjaro®References
- StatPearls (NCBI Bookshelf) — Pharmacology and clinical use of Tirzepatide
View Source - New England Journal of Medicine (2022) — Tirzepatide for the treatment of obesity
View Source - FDA Prescribing Information — Mounjaro (tirzepatide) prescribing information
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mounjaro® / Zepbound® · Type 2 diabetes / Obesity (2022)
Mounjaro® · Type 2 diabetes (2022)
Mounjaro® · Type 2 diabetes (2023)
Mounjaro® · Type 2 diabetes (2024)
Mounjaro® · Type 2 diabetes / Obesity (2023)
Mounjaro® · Type 2 diabetes (2023)
Approved worldwide (6+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →